Investors are always looking for stocks that are poised to beat at earnings season and Royalty Pharma plc (RPRX) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Royalty Pharma is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty ...

The upcoming report from Royalty Pharma (RPRX) is expected to reveal quarterly earnings of $0.96 per share, indicating a decline of 40% compared to the year-ago period. Analysts forecast revenues of $671.45 million, representing a decrease of 40.6% year over year.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a co ...

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on June 14, 2024, to shareholders of record at the close of business on May 17, 2024. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collabora ...

Royalty Pharma (RPRX) reported $736 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 30.8%. EPS of $1.15 for the same period compares to $1.56 a year ago.The reported revenue represents a surprise of +4.71% over the Zacks Consensus Estimate of $702.9 million. With the consensus EPS estimate being $1.03, the EPS surprise was +11.65%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

Royalty Pharma PLC (NASDAQ:RPRX) Q4 2023 Earnings Conference Call February 15, 2024 8:00 AM ET Company Participants Pablo Legorreta - Founder, Chairman & CEO Chris Hite - Vice Chairman & EVP Terrance Coyne - EVP & CFO Marshall Urist - EVP & Head, Research & Investments George Grofik - SVP & Head of IR & Communications Conference Call Participants Geoff Meacham - Bank of America Chris Schott - J.P. Morgan Terence Flynn - Morgan Stanley Chris Shibutani - Goldman Sachs Steve Scala - TD Cowen Operator Ladies an ...

| --- | --- | --- | --- | |-------------------------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------------| | 1 1 | | 3 | 4 | | Financial | Portfolio | Capital allocation | Full-year guidance | | Strong portfolio growth, including the CF franchise, Trelegy, Tremfya a ...

Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY 2023Announced transactions of up to $4.0 billion in 2023Full year 2024 guidance: Portfolio Receipts of $2,600 to $2,700 million (reflecting royalty receipts growth of 5% to 9% year/year) excluding future transactions NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the fourth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR For the transition period from _________ to __________ Commission file number 001-39329 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (St ...

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call informa ...

NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's dividend. The dividend will be paid on March 15, 2024 to shareholders of record at the close of business on February 16, 2024. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutic ...